Ostiral (Raloxifene Hydrochloride)

Raloxifene Hydrochloride, the active ingredient in Ostiral, is a selective estrogen receptor modulator presented as a tablet for oral use. It is used to treat and prevent osteoporosis in postmenopausal women. GNH USA supplies Ostiral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ostiral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ostiral is a selective estrogen receptor modulator that acts on bone metabolism pathways to improve skeletal health.

- Post‑menopausal osteoporosis: reduces risk of vertebral fractures and increases bone mineral density. - Osteopenia: helps maintain bone density and may delay progression to osteoporosis. - Secondary osteoporosis due to glucocorticoid therapy: supports bone strength when steroids are required long‑term.

Adverse reactions to raloxifene are reported across a spectrum of frequency.

Common Side Effects: - Hot flashes - Leg cramps or muscle aches - Swelling of the feet or ankles - Nausea or mild gastrointestinal discomfort - Vaginal dryness or discharge

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Stroke, particularly in women with cardiovascular risk factors - Severe allergic reactions such as angioedema - Sudden vision changes indicating retinal artery occlusion

When prescribing Ostiral, clinicians should consider several safety aspects.

- Thromboembolic risk: assess patient history of clotting disorders before initiating therapy. - Cardiovascular health: monitor blood pressure and lipid profile in patients with existing heart disease. - Liver function: evaluate hepatic enzymes periodically as raloxifene is metabolized hepatically. - Menopausal symptoms: counsel patients about possible hot flashes and provide management strategies. - Bone health monitoring: schedule regular bone mineral density tests to gauge treatment effectiveness. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Raloxifene may interact with several concomitant medicines, requiring vigilance.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole) – may increase plasma levels of raloxifene. - Estrogen‑containing hormone therapy, estrogen patches  :                                                                                                                                                                                                                                                                                                                                 ...